Single Session Combined Locoregional Therapies for Hepatocellular Carcinoma

• Status: Recruiting
• Trial end date: 2023-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Hepatocellular carcinoma is the third most common cause of cancer-related mortality. In recent years, transarterial chemoembolization, radio frequency ablation and microwave ablation have been accepted as treatment modalities for patients with surgically unresectable hepatocellular carcinoma.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sherief Abd-Elsalam
• Collaborator: Tanta University
• Treatments: Chlorotrianisene

Criteria

Inclusion Criteria:

• Child classification A or B.

• serum albumin ≥ 3 gm/L.

• serum bilirubin < 2.5 mg/dL.

• platelet count ≥70,000 mm3.

• INR ≤ 1.6.

• serum creatinine < 2 mg/dl.

• tumor size more than 4 cm and confined to one lobe of the liver.

Exclusion Criteria:

• Patients with portal vein thrombosis.

• A technically inaccessible hepatic artery.

• Metastatic HCC.

• More than three lesions.

• lesions in close proximity to the portal vein (PV),inferior vena cava (IVC) or gall bladder were excluded from the study.